

"Express Mail" mailing label number EL018700462US

Date of Deposit

Jan. 23, 02

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

QUEEN THOMAS  
Printed Name

Queen Thomas  
Signature

**PATENT APPLICATION**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

The Accompanying Application

Applicant : Chin-Ming Chang and Henry A. Havel

For : STABILIZED TERIPARATIDE SOLUTIONS

Docket No. : X10911A

**PRELIMINARY AMENDMENT**

Assistant Commissioner for Patents

Washington, D. C. 20231

Sir:

Please amend the accompanying application as follows:

**In the Claims**

Please cancel original claims 1-25.

Please add new claims 26-35:

26. A pharmaceutical composition in the form of a solution, which comprises human parathyroid hormone and a buffer to maintain a pH from greater than 3 to about 7, said solution being ready for parenteral administration in a human patient without having been freeze dried.

27. The pharmaceutical of claim 26, wherein said buffer is selected from citrate, tartrate, or acetate.

28. The pharmaceutical of claim 26, said solution further comprising a stabilizer.
29. The pharmaceutical of claim 28, wherein said stabilizer is mannitol.
30. The pharmaceutical of claim 26, wherein said human parathyroid hormone is selected from the group consisting of PTH(1-31), PTH(1-34), PTH(1-37), PTH(1-38), PTH(1-41) and PTH(1-84).
31. The pharmaceutical of claim 30, wherein said human parathyroid hormone is PTH(1-84).
32. The pharmaceutical of claim 30, wherein said human parathyroid hormone is PTH(1-34).
33. A pharmaceutical composition in the form of a solution, which comprises human parathyroid hormone and a buffer to maintain a pH from greater than 3 to about 7, said solution being ready for parenteral administration in a human patient without reconstitution.
34. The pharmaceutical of claim 26, wherein said solution further comprises a parenterally acceptable preservative.
35. The pharmaceutical of claim 33, wherein said solution further comprises a parenterally acceptable preservative.

**Remarks**

Applicants request entry of the foregoing amendment.  
Support for claims 26-35 is found at multiple places in the  
specification including page 2-3 and page 5.

Respectfully submitted,



Thomas D. Webster  
Attorney for Applicant  
Registration No. 39,872  
Phone: 317-276-9934

Eli Lilly and Company  
Patent Division/TDW  
Lilly Corporate Center  
Indianapolis, Indiana 46285

January 23, 2002